With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
The phase 3 PREMER trial (n=118) demonstrates higher rates of delayed recall when receiving prophylactic cranial irradiation without versus with hippocampal avoidance at months 3 (22 → 5%) and 6 (33 → 7%). | De Dios, ASTRO 2019